Abstract:figure legend Considerations for altitude travel in pulmonary vascular disease patients, focusing on sensible pre‐travel evaluation, possible altitude‐related adverse events and their management. Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension are the main precapillary forms of pulmonary hypertension (PH) summarized as pulmonary vascular diseases (PVD). PVDs are characterized by exertional dyspnoea and oxygen desaturation, and reduced quality of life and survival. Medical therapies improve life expectancy and physical performance of PVD patients, of whom many wish to participate in professional work and recreational activities including traveling to high altitude. The exposure to the hypobaric hypoxic environment of mountain regions incurs the risk of high altitude adverse events (AEHA) due to severe hypoxaemia exacerbating symptoms and further increase in pulmonary artery pressure, which may lead to right heart decompensation. Recent prospective and randomized trials show that altitude‐induced hypoxaemia, pulmonary haemodynamic changes and impairment of exercise performance in PVD patients are in the range found in healthy people. The vast majority of optimally treated stable PVD patients who do not require long‐term oxygen therapy at low altitude can tolerate short‐term exposure to moderate altitudes up to 2500 m. PVD patients that reveal persistent severe resting hypoxaemia (SpO2 30 min) at 2500 m respond well to supplemental oxygen therapy. Although there are no accurate predictors for AEHA, PVD patients with unfavourable risk profiles at low altitude, such as higher WHO functional class, lower exercise capacity with more pronounced exercise‐induced desaturation and more severely impaired haemodynamics, are at increased risk of AEHA. Therefore, doctors with experience in PVD and high‐altitude medicine should counsel PVD patients before any high‐altitude sojourn. This review aims to summarize recent literature and clinical recommendations about PVD patients travelling to high altitude.

Problems of Air Travel for Patients with Lung Disease

Flying with Respiratory Disease

Helping patients travel by air

Incidence of Oxygen Desaturation Using a High-Flow Nasal Cannula Versus a Facemask During Flexible Bronchoscopy in Patients at Risk of Hypoxemia: a Randomised Controlled Trial

Hearts in the sky: understanding the cardiovascular implications of air travel

Implications of the hypobaric cabin environment during commercial air travel for passenger fitness to fly

Are pulmonologists well aware of planning safe air travel for patients with COPD? The SAFCOP study

AsMA Medical Guidelines for Air Travel: stresses of flight

[Medical problems among airline passengers]

Traveling With Cancer: A Guide for Oncologists in the Modern World

A chronic pneumothorax and fitness to fly

Flying to high-altitude destinations

Underlying lung disease and exposure to terrestrial moderate and high altitude: personalised risk assessment

Are patients with cognitive impairment fit to fly? Current evidence and practical recommendations

Hypercapnic Respiratory Acidosis During An In-Flight Oxygen Assessment

Assessing air travel safety in neuromuscular disease: standard versus prolonged hypoxic challenge tests

Symposium review: high altitude travel with pulmonary vascular disease

Pneumothorax and Timing to Safe Air Travel

Fitness to fly for children and adolescents after Fontan palliation

Contributions of Hypoxia-Awareness Training to the Familiarization of Personal Symptoms for Occupational Safety in the Flight Environment